The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
NCT00914667
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Healthy male and/or female subjects between the ages of 18 and 55 years
- Not healthy subjects--subjects with acute or chronic medical or psychiatric conditions
or laboratory abnormality
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Seoul,
- Wien,
- Antwerpen,
- Edegem,
- Gent,
- Kortrijk,
- Aarhus N,
- Glostrup,
- Helsinki,
- Kouvola,
- OYS,
- Tampere,
- Turku,
- Berlin,
- Berlin,
- Frankfurt,
- Hannover,
- Leipzig,
- Muenchen,
- Haifa,
- Haifa,
- Jerusalem,
- Foggia,
- Terracina, LT,
- Hamar,
- Oslo,
- Tonsberg,
- Trondheim,
- Coimbra,
- Lisboa,
- Porto,
- Porto,
- Porto,
- Bratislava,
- Bratislava,
- Galanta,
- Kosice - Saca,
- Kosice,
- Martorell, Barcelona
- Sabadell, Barcelona
- Getafe, Madrid
- Manacor, Palma de Mallorca
- Valencia,
- Eslov,
- Goteborg,
- Malmo,
- Malmo,
- Norrkoping,
- Stockholm,
- Frauenfeld,
- Ankara,
- Istanbul,
- Izmir,
- Samsun,
- Bexhill on Sea, East Sussex
- Leytonstone, London
- Harrow, Middlesex
- High Heaton, Newcastle upon Tyne
- Birmingham,
- London,
- London,
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Huntsville, Alabama
- Montgomery, Alabama
- Phoenix, Arizona
- Sun Lakes, Arizona
- Bentonville, Arkansas
- Jonesboro, Arkansas
- Little Rock, Arkansas
- Buena Park, California
- Foothill Ranch, California
- Fresno, California
- West Covina, California
- Colorado Springs, Colorado
- Lakewood, Colorado
- Chipley, Florida
- Davie, Florida
- Hallandale, Florida
- Miami Beach, Florida
- Miami, Florida
- Murdock, Florida
- Ocala, Florida
- Pembroke Pines, Florida
- St. Cloud, Florida
- Tampa, Florida
- Atlanta, Georgia
- Barnesville, Georgia
- Blue Ridge, Georgia
- Decatur, Georgia
- Chicago, Illinois
- Naperville, Illinois
- Orland Park, Illinois
- Newton, Kansas
- Shawnee, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Marrero, Louisiana
- Laurel, Maryland
- Oxon Hill, Maryland
- Jackson, Michigan
- Portage, Michigan
- St. Louis, Missouri
- Las Vegas, Nevada
- Las Vegas, Nevada
- Blackwood, New Jersey
- Mt. Laurel, New Jersey
- Binghamton, New York
- Endicott, New York
- Endwell, New York
- Kingston, New York
- Beaufort, North Carolina
- Charlotte, North Carolina
- Charlotte, North Carolina
- Durham, North Carolina
- Morehead City, North Carolina
- Winston-Salem, North Carolina
- Columbus, Ohio
- Kettering, Ohio
- Central Point, Oregon
- Medford, Oregon
- Bala Cynwyd, Pennsylvania
- Bensalem, Pennsylvania
- Connellsville, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Sellersville, Pennsylvania
- Stoneboro, Pennsylvania
- Warwick, Rhode Island
- Greer, South Carolina
- Simpsonville, South Carolina
- Cordova, Tennessee
- Huntingdon, Tennessee
- Lexington, Tennessee
- Savannah, Tennessee
- Selmer, Tennessee
- Waynesboro, Tennessee
- Austin, Texas
- Bryan, Texas
- Colleyville, Texas
- Friendswood, Texas
- Houston, Texas
- Plano, Texas
- Plano, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- West Jordan, Utah
- West Valley City, Utah
- Spokane, Washington
- Spokane, Washington
- Milwaukee, Wisconsin
- New Berlin, Wisconsin
- Oregon, Wisconsin
- Wauwatosa, Wisconsin
- Singapore,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects | |||
Official Title ICMJE | An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Fesoterodine On The Pharmacokinetics And Pharmacodynamics Of A Single Supratherapeutic Dose Of Warfarin In Healthy Subjects. | |||
Brief Summary | This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Urinary Bladder, Overactive | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Estimated Enrollment ICMJE | 14 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | August 2009 | |||
Actual Primary Completion Date | August 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 55 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00914667 | |||
Other Study ID Numbers ICMJE | A0221079 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | May 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |